BACKGROUND: We sought to evaluate the association of metabolic syndrome (MetS) and computed tomography (CT)-derived cardiometabolic biomarkers (non-alcoholic fatty liver disease [NAFLD] and epicardial adipose tissue [EAT] measures) with long-term risk of major adverse cardiovascular events (MACE) in asymptomatic individuals. METHODS: This was a post-hoc analysis of the prospective EISNER (Early-Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) study of participants who underwent baseline coronary artery calcium (CAC) scoring CT and 14-year follow-up for MACE (myocardial infarction, late revascularization, or cardiac death). EAT volume (cm3) and attenuation (Hounsfield units [HU]) were quantified from CT using fully automated deep learning software (< 30 s per case). NAFLD was defined as liver-to-spleen attenuation ratio < 1.0 and/or average liver attenuation < 40 HU. RESULTS: In the final population of 2068 participants (59% males, 56 ± 9 years), those with MetS (n = 280;13.5%) had a greater prevalence of NAFLD (26.0% vs. 9.9%), higher EAT volume (114.1 cm3 vs. 73.7 cm3), and lower EAT attenuation (-76.9 HU vs. -73.4 HU; all p < 0.001) compared to those without MetS. At 14 ± 3 years, MACE occurred in 223 (10.8%) participants. In multivariable Cox regression, MetS was associated with increased risk of MACE (HR 1.58 [95% CI 1.10-2.27], p = 0.01) independently of CAC score; however, not after adjustment for EAT measures (p = 0.27). In a separate Cox analysis, NAFLD predicted MACE (HR 1.78 [95% CI 1.21-2.61], p = 0.003) independently of MetS, CAC score, and EAT measures. Addition of EAT volume to current risk assessment tools resulted in significant net reclassification improvement for MACE (22% over ASCVD risk score; 17% over ASCVD risk score plus CAC score). CONCLUSIONS: MetS, NAFLD, and artificial intelligence-based EAT measures predict long-term MACE risk in asymptomatic individuals. Imaging biomarkers of cardiometabolic disease have the potential for integration into routine reporting of CAC scoring CT to enhance cardiovascular risk stratification. Trial registration NCT00927693.
BACKGROUND: We sought to evaluate the association of metabolic syndrome (MetS) and computed tomography (CT)-derived cardiometabolic biomarkers (non-alcoholic fatty liver disease [NAFLD] and epicardial adipose tissue [EAT] measures) with long-term risk of major adverse cardiovascular events (MACE) in asymptomatic individuals. METHODS: This was a post-hoc analysis of the prospective EISNER (Early-Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) study of participants who underwent baseline coronary artery calcium (CAC) scoring CT and 14-year follow-up for MACE (myocardial infarction, late revascularization, or cardiac death). EAT volume (cm3) and attenuation (Hounsfield units [HU]) were quantified from CT using fully automated deep learning software (< 30 s per case). NAFLD was defined as liver-to-spleen attenuation ratio < 1.0 and/or average liver attenuation < 40 HU. RESULTS: In the final population of 2068 participants (59% males, 56 ± 9 years), those with MetS (n = 280;13.5%) had a greater prevalence of NAFLD (26.0% vs. 9.9%), higher EAT volume (114.1 cm3 vs. 73.7 cm3), and lower EAT attenuation (-76.9 HU vs. -73.4 HU; all p < 0.001) compared to those without MetS. At 14 ± 3 years, MACE occurred in 223 (10.8%) participants. In multivariable Cox regression, MetS was associated with increased risk of MACE (HR 1.58 [95% CI 1.10-2.27], p = 0.01) independently of CAC score; however, not after adjustment for EAT measures (p = 0.27). In a separate Cox analysis, NAFLD predicted MACE (HR 1.78 [95% CI 1.21-2.61], p = 0.003) independently of MetS, CAC score, and EAT measures. Addition of EAT volume to current risk assessment tools resulted in significant net reclassification improvement for MACE (22% over ASCVD risk score; 17% over ASCVD risk score plus CAC score). CONCLUSIONS: MetS, NAFLD, and artificial intelligence-based EAT measures predict long-term MACE risk in asymptomatic individuals. Imaging biomarkers of cardiometabolic disease have the potential for integration into routine reporting of CAC scoring CT to enhance cardiovascular risk stratification. Trial registration NCT00927693.
Authors: Anand Rohatgi; Andrew W Owens; Amit Khera; Colby R Ayers; Kamakki Banks; Sandeep R Das; Jarett D Berry; Darren K McGuire; James A de Lemos Journal: Arterioscler Thromb Vasc Biol Date: 2009-10 Impact factor: 8.311
Authors: Andrew W Owens; Susan Matulevicius; Anand Rohatgi; Colby R Ayers; Sandeep R Das; Amit Khera; Darren K McGuire; James A de Lemos Journal: Atherosclerosis Date: 2010-06-11 Impact factor: 5.162
Authors: Irfan Zeb; Dong Li; Matthew J Budoff; Ronit Katz; Donald Lloyd-Jones; Arthur Agatston; Roger S Blumenthal; Michael J Blaha; Ron Blankstein; Jeffrey Carr; Khurram Nasir Journal: J Am Coll Cardiol Date: 2016-04-26 Impact factor: 24.094
Authors: Salvatore Mottillo; Kristian B Filion; Jacques Genest; Lawrence Joseph; Louise Pilote; Paul Poirier; Stéphane Rinfret; Ernesto L Schiffrin; Mark J Eisenberg Journal: J Am Coll Cardiol Date: 2010-09-28 Impact factor: 24.094
Authors: Michael T Lu; Jakob Park; Khristine Ghemigian; Thomas Mayrhofer; Stefan B Puchner; Ting Liu; Jerome L Fleg; James E Udelson; Quynh A Truong; Maros Ferencik; Udo Hoffmann Journal: Atherosclerosis Date: 2016-05-20 Impact factor: 5.162
Authors: Federico Greco; Rodrigo Salgado; Wim Van Hecke; Romualdo Del Buono; Paul M Parizel; Carlo Augusto Mallio Journal: Quant Imaging Med Surg Date: 2022-03
Authors: Jessica Carter; Thomas D Heseltine; Mohammed N Meah; Evangelos Tzolos; Jacek Kwiecinski; Mhairi Doris; Priscilla McElhinney; Alastair J Moss; Philip D Adamson; Amanda Hunter; Shirjel Alam; Anoop S V Shah; Tania Pawade; Chengjia Wang; Jonathan R Weir-McCall; Giles Roditi; Edwin J R van Beek; Edward D Nicol; Leslee J Shaw; Daniel S Berman; Piotr J Slomka; Nicholas L Mills; Marc R Dweck; David E Newby; Scott W Murray; Damini Dey; Michelle C Williams Journal: Radiol Cardiothorac Imaging Date: 2022-04-28
Authors: Kyra K Peczkowski; Mohammed A Mashali; Nancy S Saad; Austin Hare; Courtney M Campbell; Bryan A Whitson; Nahush A Mokadam; Paul M L Janssen Journal: J Am Heart Assoc Date: 2022-06-22 Impact factor: 6.106
Authors: Ramyashree Tummala; Donghee Han; John Friedman; Sean Hayes; Louise Thomson; Heidi Gransar; Piotr Slomka; Alan Rozanski; Damini Dey; Daniel Berman Journal: Am J Prev Cardiol Date: 2022-09-27